0001209191-22-055828.txt : 20221104 0001209191-22-055828.hdr.sgml : 20221104 20221104172345 ACCESSION NUMBER: 0001209191-22-055828 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221102 FILED AS OF DATE: 20221104 DATE AS OF CHANGE: 20221104 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Schor Chen CENTRAL INDEX KEY: 0001340875 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38359 FILM NUMBER: 221363134 MAIL ADDRESS: STREET 1: PREDIX PHARMACEUTICALS HOLDINGS, INC. STREET 2: 4 MAGUIRE ROAD CITY: LEXINGTON STATE: MA ZIP: 02421 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Adicet Bio, Inc. CENTRAL INDEX KEY: 0001720580 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 813305277 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 BERKELEY STREET STREET 2: 19TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 617-482-2333 MAIL ADDRESS: STREET 1: 200 BERKELEY STREET STREET 2: 19TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 FORMER COMPANY: FORMER CONFORMED NAME: resTORbio, Inc. DATE OF NAME CHANGE: 20171024 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-11-02 0 0001720580 Adicet Bio, Inc. ACET 0001340875 Schor Chen C/O ADICET BIO, INC. 200 BERKELEY STREET, 19TH FLOOR BOSTON MA 02116 1 1 0 0 President & CEO Common Stock 2022-11-02 4 S 0 500 18.00 D 138237 I See Footnote Common Stock 2022-11-03 4 S 0 24813 18.0437 D 113424 I See Footnote Common Stock 101424 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Represents shares held directly by The C. Schor IRRV Trust, an irrevocable family trust having an independent trustee. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $18.00 to $18.25, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the Securities and Exchange Commission staff upon request. /s/ Nick Harvey, Attorney-in-Fact 2022-11-04